MYC and non-small cell lung carcinoma: NSCLC patients with both positive MYC expression and positive PD-L1 expression had poorer OS (HR: 5.223; 95% CI: 2.236 to 12.201; P = 0.000) than patients with double-negative expression, which indicated that MYC could be a potential marker for response assessment of immune checkpoint inhibitor therapy [60].